Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 2, 2014, Pages 223-229

  Furuta, Atsushi ^a,b   Salam, Kazi Abdus ^c   Akimitsu, Nobuyoshi ^c   Tanaka, Junichi ^d   Tani, Hidenori ^b   Yamashita, Atsuya ^e   Moriishi, Kohji ^e   Nakakoshi, Masamichi ^f   Tsubuki, Masayoshi ^f   Sekiguchi, Yuji ^b   Tsuneda, Satoshi ^a   Noda, Naohiro ^a,b  

^a WASEDA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f HOSHI UNIVERSITY   (Japan)

Author keywords

Cholesterol sulfate; Hepatitis C virus; Marine organism; NS3 helicase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BIS(SODIUM SULFOPROPYL)DISULFIDE; CHOLESTEROL; CHOLESTEROL SULFATE; DI N BUTYL SULFATE; DODECYL SULFATE SODIUM; NONSTRUCTURAL PROTEIN 3; PRASTERONE SULFATE; RNA HELICASE; SERINE PROTEINASE; SODIUM SULFATE; SULFATE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG EFFECT; DRUG ISOLATION; DRUG PURIFICATION; DRUG SCREENING; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS; HYDROPHOBICITY; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; STEROL ANALYSIS;

ADENOSINE TRIPHOSPHATASES; ANTIVIRAL AGENTS; AQUATIC ORGANISMS; CHOLESTEROL ESTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HEPACIVIRUS; MOLECULAR STRUCTURE; PROTEIN BINDING; RNA HELICASES; SERINE PROTEASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84892899537     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.766607     Document Type: Article

References (33)

1. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011;8:69-71.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
4. Opar A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov 2010;9:501-3.
5. Lam AM, Frick DN. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 2006;80:404-11.
6. Kwong AD, Rao BG, Jeang KT. Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov 2005;4:845-53.
7. Gallinari P, Brennan D, Nardi C, et al. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998;72:6758-69.
8. Kim DW, Gwack Y, Han JH, Choe J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 1995;215:160-6.
9. Tai CL, Chi WK, Chen DS, Hwang LH. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 1996;70:8477-84.
10. Gwack Y, Kim DW, Han JH, Choe J. Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem Biophys Res Commun 1996;225:654-9.
11. Gwack Y, Kim DW, Han JH, Choe J. DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur J Biochem 1997;250:47-54.
12. Belon CA, Frick DN. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol 2009;4:277-93.
13. Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011;10:188-95.
14. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77.
15. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009;325:161-5.
16. Salomon CE, Magarvey NA, Sherman DH. Merging the potential of microbial genetics with biological and chemical diversity: an even brighter future for marine natural product drug discovery. Nat Prod Rep 2004;21:105-21.
17. Tani H, Akimitsu N, Fujita O, et al. High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem Biophys Res Commun 2009;379:1054-9.
18. Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. New York: Wiley; 2005:111-40.
19. Salam KA, Furuta A, Noda N, et al. Inhibition of hepatitis C virus NS3 helicase by manoalide. J Nat Prod 2012;75:650-4.
20. Stankiewicz-Drogon A, Palchykovska LG, Kostina VG, et al. New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection. Bioorg Med Chem 2008;16:8846-52.
21. Mikkelsen NE, Johansson K, Virtanen A, Kirsebom LA. Aminoglycoside binding displaces a divalent metal ion in a tRNAneomycin B complex. Nat Struct Biol 2001;8:510-14.
22. Huang Y, Liu ZR. The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase. J Biol Chem 2002;277:12810-15.
23. Frick DN, Ginzburg O, Lam AM. A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities. Methods Mol Biol 2010;587:223-33.
24. Dahl G, Sandstrom A, Akerblom E, Danielson UH. Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. FEBS J 2007; 274:5979-86.
25. Frick DN. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol 2007;9:1-20.
26. Strott CA, Higashi Y. Cholesterol sulfate in human physiology: what's it all about? J Lipid Res 2003;44:1268-78.
27. Iwamori M, Iwamori Y, Ito N. Sulfated lipids as inhibitors of pancreatic trypsin and chymotrypsin in epithelium of the mammalian digestive tract. Biochem Biophys Res Commun 1997;237:262-5.
28. Iwamori M, Iwamori Y, Ito N. Regulation of the activities of thrombin and plasmin by cholesterol sulfate as a physiological inhibitor in human plasma. J Biochem 1999;125:594-601.
29. Sato J, Denda M, Nakanishi J, et al. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. J Invest Dermatol 1998;111:189-93.
30. Ito N, Iwamori Y, Hanaoka K, Iwamori M. Inhibition of pancreatic elastase by sulfated lipids in the intestinal mucosa. J Biochem 1998;123:107-14.
31. Iwamori M, Suzuki H, Kimura T, Iwamori Y. Shedding of sulfated lipids into gastric fluid and inhibition of pancreatic DNase I by cholesterol sulfate in concert with bile acids. Biochim Biophys Acta 2000;1487:268-74.
32. Raney KD, Sharma SD, Moustafa IM, Cameron CE. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010;285:22725-31.
33. Suzich JA, Tamura JK, Palmer-Hill F, et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol 1993;67:6152-8.